GleamWall
中文EN

ADMA ADMA BIOLOGICS, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1368514 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY6.3%
TTM net income YoY-12.9%
TTM EPS YoY-10.5%
Revenue 3-yr CAGR30.4%
Net income 3-yr CAGR—

Margins

Gross margin68.5%
Operating margin46.5%
Net margin35.1%
FCF margin25.6%
EBITDA margin47.9%

Returns

ROE41.9%
ROA28.0%
ROIC (approx.)39.4%
Asset turnover0.80x

Leverage & solvency

Liabilities / assets40.1%
Debt / equity0.45x
Current ratio6.04x
Interest coverage22.80x

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio6.4%
Payout ratio—
Capex / revenue1.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$510.17M$426.45M
Cost of revenue$217.41M$206.90M
Gross profit$292.76M$219.55M
R&D expense$4.76M$1.81M
SG&A expense$91.58M$74.12M
Operating income$191.44M$138.98M
Interest expense$7.11M$13.93M
Pretax income$182.66M$125.71M
Income tax$35.73M-$71.96M
Net income$146.93M$197.67M
EBITDA$199.44M$146.68M
EPS (basic)0.620.85
EPS (diluted)0.600.81
Weighted avg. shares (diluted)244.90M243.34M
Balance sheet
Cash & equivalents$87.63M$103.15M
Receivables$158.43M$50.00M
Inventory$206.47M$170.24M
Current assets$466.51M$331.41M
PP&E, net$65.06M$54.71M
Goodwill$3.53M$3.53M
Intangibles$632,000$460,000
Total assets$624.24M$488.68M
Current liabilities$69.54M$55.54M
Short-term debt$2.81M$0
Long-term debt$69.33M$72.34M
Total debt$72.14M$72.34M
Total liabilities$146.92M$139.66M
Shareholders' equity$477.32M$349.02M
Net debt-$15.49M-$30.81M
Shares outstanding237.87M236.62M
Cash flow statement
Operating cash flow$50.40M$118.67M
Capital expenditure$22.57M$8.23M
Free cash flow$27.82M$110.45M
Investing cash flow-$21.89M-$8.57M
Financing cash flow-$44.02M-$58.30M
Depreciation & amortization$8.00M$7.70M
Stock-based compensation$20.03M$13.62M
Share buybacks$31.94M$0

Free plan shows the latest 2 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.